PUPH Researchers Find Haplo-HSCT Superior to Chemotherapy for Int-risk AML CR1
Researchers at Peking University People’s Hospital found strong clinical evidence for treatment choice in intermediate-risk acute myelogenous leukemia (AML) in first complete remission. The study, titled “Haplo-HSCT Is Superior to Chemotherapy for Int-risk AML CR1”, was conducted by a group led by Prof. Huang Xiaojun, and appeared in the March issue of Clinical Cancer Research , journal of the American Association for Cancer Research (AACR).
Previously, this same group had developed the so-called Beijing Protocol of myeloablative HLA haploidentical hematopoietic stem cell transplantation (haplo-HSCT) following pretransplant anti-thymocyte globulin (ATG) and granulocyte colony-stimulating factor (G-CSF) stimulated grafts (ATG+G-CSF), as an alternative to conventional HSCT from HLA-matched sibling donors (MSD). The recently published article showed that the haplo-HSCT group had higher 3-year leukemia-free survival (LFS) and overall survival (OS) than the chemotherapy group, and that postremission treatment (haplo-HSCT vs. chemotherapy) was an independent risk factor affecting the LFS, OS and cumulative incidence of relapse.
Written by: Fan Xiaofei
Edited by: Liu Xin